FrancophonIA/ELRC3.0 huggingface dataset:
English: INFORMATION IN BRAILLE SIFROL 2.1 mg prolonged-release tablets 17.
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) SIFROL 2,1 mg toimeainet prolongeeritult vabastavad tabletid
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/016 [10 prolonged-release tablets] EU/1/97/050/017 [30 prolonged-release tablets] EU/1/97/050/018 [100 prolonged-release tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/016 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/017 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/018 [100 toimeainet prolongeeritult vabastavat tabletti]
English: NAME OF THE MEDICINAL PRODUCT SIFROL 0.18 mg tablets Pramipexole
Estonian: RAVIMPREPARAADI NIMETUS SIFROL 0,18 mg tabletid Pramipexolum
English: Store in the original package to protect the tablets from light.
Estonian: Hoida originaalpakendis valguse eest kaitstult.
English: In the absence of human data, SIFROL should not be used during breast-feeding.
Estonian: Rottidel olid toimeainega seotud radioaktiivsus emapiimas kõrgem kui vereplasmas.Inimestel saadud andmete puudumise tõttu ei tohi SIFROL'i kasutada rinnaga toitmise ajal.
English: NAME OF THE MEDICINAL PRODUCT SIFROL 2.1 mg prolonged-release tablets Pramipexole
Estonian: RAVIMPREPARAADI NIMETUS SIFROL 2,1 mg toimeainet prolongeeritult vabastavad tabletid Pramipexolum
English: NAME OF THE MEDICINAL PRODUCT SIFROL 0.26 mg prolonged-release tablets Pramipexole
Estonian: RAVIMPREPARAADI NIMETUS SIFROL 0,26 mg toimeainet prolongeeritult vabastavad tabletid Pramipexolum
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/025 [10 prolonged-release tablets] EU/1/97/050/026 [30 prolonged-release tablets] EU/1/97/050/027 [100 prolonged-release tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/025 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/026 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/027 [100 toimeainet prolongeeritult vabastavat tabletti]
English: Ascending dose schedule of SIFROL prolonged-release tablets Week Daily dose (mg of base)
Estonian: SIFROL toimeainet prolongeeritult vabastavate tablettide tõusva annustamise skeem Nädal
English: 4 tablets SIFROL 0.088 mg
Estonian: Neli SIFROL 0,088 mg tabletti
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/013 [10 prolonged-release tablets] EU/1/97/050/014 [30 prolonged-release tablets] EU/1/97/050/015 [100 prolonged-release tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/013 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/014 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/015 [100 toimeainet prolongeeritult vabastavat tabletti]
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/031 [10 prolonged-release tablets] EU/1/97/050/032 [30 prolonged-release tablets] EU/1/97/050/033 [100 prolonged-release tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/031 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/032 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/033 [100 toimeainet prolongeeritult vabastavat tabletti]
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/028 [10 prolonged-release tablets] EU/1/97/050/029 [30 prolonged-release tablets] EU/1/97/050/030 [100 prolonged-release tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/028 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/029 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/030 [100 toimeainet prolongeeritult vabastavat tabletti]
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/022 [10 prolonged-release tablets] EU/1/97/050/023 [30 prolonged-release tablets] EU/1/97/050/024 [100 prolonged-release tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/022 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/023 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/024 [100 toimeainet prolongeeritult vabastavat tabletti]
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/011 [30 tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/011 [30 tabletti] EU/1/97/050/012 [100 tabletti]
English: SIFROL prolonged-release tablets are a once-a-day oral formulation of pramipexole.
Estonian: SIFROL toimeainet prolongeeritult vabastavad tabletid on pramipeksooli koostis, mida kasutatakse üks kord ööpäevas suukaudselt.
English: 6 tablets SIFROL 0.088 mg
Estonian: Kuus SIFROL 0,088 mg tabletti
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/019 [10 prolonged-release tablets] EU/1/97/050/020 [30 prolonged-release tablets] EU/1/97/050/021 [100 prolonged-release tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/019 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/020 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/97/050/021 [100 toimeainet prolongeeritult vabastavat tabletti]
English: Maize starch
Estonian: Harv kuni
English: 2 tablets SIFROL 0.088 mg
Estonian: Kaks SIFROL 0,088 mg tabletti
English: 1 tablet SIFROL 0.35 mg OR
Estonian: Üks SIFROL 0,35 mg tablett
English: SIFROL 0.26 mg prolonged-release tablets
Estonian: Üks SIFROL 0,26 mg toimeainet prolongeeritult vabastav tablett.
English: 1 tablet SIFROL 0.088 mg
Estonian: Üks SIFROL 0,088 mg tablett
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/005 [30 tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/005 [30 tabletti] EU/1/97/050/006 [100 tabletti]
English: 2 tablets SIFROL 0.18 mg OR
Estonian: Kaks SIFROL 0,18 mg tabletti
English: 3 tablets SIFROL 0.18 mg OR
Estonian: Kolm SIFROL 0,18 mg tabletti
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/003 [30 tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/003 [30 tabletti] EU/1/97/050/004 [100 tabletti]
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/001 [30 tablets]
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/97/050/001 [30 tabletti] EU/1/97/050/002 [100 tabletti]
English: C.
Estonian: KG
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine Hexal on 11 December 2009.
Estonian: Euroopa Komisjon andis Rivastigmine Hexali müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 11. detsembril 2009.
English: The full EPAR for Rivastigmine Hexal can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Rivastigmine Hexali kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Rivastigmine Hexal should be given twice a day, with morning and evening meals.
Estonian: Rivastigmine Hexalit manustatakse kaks korda ööpäevas, hommiku- ja õhtusöögi ajal.
English: This authorisation was based on the authorisation granted to Exelon in 1998 (‘informed consent').
Estonian: Müügiluba põhineb 1998. aastal antud Exeloni müügiloal (teabel põhineva nõusoleku alusel).
English: It is available as capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg) and as an oral solution (2 mg/ml).
Estonian: Seda turustatakse kapslitena (1,5 mg, 3 mg, 4,5 mg ja 6 mg) ja suukaudse lahusena (2 mg/ml).
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Rivastigmine Hexal by the patient.
Estonian: Ravi tohib alustada vaid sel juhul, kui on olemas hooldaja, kes jälgib regulaarselt, kuidas patsient kasutab Rivastigmine Hexalit.
English: The highest tolerated dose should be used to get the maximum benefit, but the dose should not exceed 6 mg twice a day.
Estonian: Selleks et ravimist oleks võimalikult palju kasu, tuleb kasutada suurimat annust, mida patsient talub, kuid annus ei tohi ületada 6 mg kaks korda ööpäevas.
English: Other information about Rivastigmine Hexal
Estonian: Muu teave Rivastigmine Hexali kohta
English: Rivastigmine Hexal has been studied in three main studies involving 2,126 patients with mild to moderately severe Alzheimer's disease.
Estonian: Rivastigmine Hexalit uuriti kolmes põhiuuringus, milles osales 2126 kerge kuni mõõdukalt raskekujulise Alzheimeri tõvega patsienti.
English: Therefore, the Committee decided that Rivastigmine Hexal's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee, et Rivastigmine Hexali kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a chemical that allows nerve cells to communicate with each other).
Estonian: Alzheimeri dementsuse või Parkinsoni tõvega kaasneva dementsusega patsientidel hävivad ajus teatud närvirakud, mille tulemusena väheneb neurotransmitteri (keemiline aine, mis vahendab signaale närvirakkude vahel) atsetüülkoliini sisaldus.
English: The Committee initially concluded that for the treatment of dementia due to Parkinson's disease, Rivastigmine Hexal's benefits did not outweigh its risks.
Estonian: Komitee jõudis algul järeldusele, et Parkinsoni tõvega kaasneva dementsuse ravis ei ole Rivastigmine Hexali kasulikkus suurem kui sellega kaasnevad riskid.
English: An additional study in 27 patients was used to show that Rivastigmine Hexal capsules and oral solution produced similar levels of the active substance in the blood.
Estonian: Täiendava uuringuga, milles osales 27 patsienti, näidati, et Rivastigmine Hexali kapslite ja suukaudse lahuse kasutamise tulemusena oli toimeaine sisaldus veres sarnane.
English: Rivastigmine Hexal is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Estonian: Rivastigmine Hexalit kasutatakse kerge kuni mõõdukalt raskekujulise Alzheimeri dementsusega patsientide raviks; see on progresseeruv ajuhäire, mis kahjustab järk-järgult mälu, vaimseid võimeid ja käitumist.
English: All of the studies lasted six months and compared the effects of Rivastigmine Hexal with those of placebo (a dummy treatment).
Estonian: Kõikide uuringute kestus oli kuus kuud ja neis võrreldi Rivastigmine Hexali toimet platseebo (näiv ravim) toimega.
English: Overall, the most common side effects include nausea (feeling sick, seen in 38 patients in 100) and vomiting (seen in 23 patients in 100), particularly during the phase when the dose of Rivastigmine Hexal is being increased.
Estonian: Kokkuvõttes on kõige sagedamad kõrvalnähud iiveldus (esinenud 38 patsiendil 100st) ja oksendamine (esinenud 23 patsiendil 100st), eelkõige Rivastigmine Hexali annuse suurendamise etapil.
English: Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects.
Estonian: Ravi tuleb jätkata, kuni ravimist on kasu, kuid kõrvalnähtude tekkimisel tohib patsiendi annust vähendada või ravi katkestada.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rivastigmine Hexal.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Rivastigmine Hexal, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Rivastigmine Hexaliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: By blocking these enzymes, Rivastigmine Hexal allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.
Estonian: Nende ensüümide blokeerimisega võimaldab Rivastigmine Hexal atsetüülkoliini sisaldusel ajus suureneda, mis aitab vähendada Alzheimeri dementsuse ja Parkinsoni tõvega kaasneva dementsuse sümptomeid.
English: In patients who tolerate this dose, it can be increased in 1.5-mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day.
Estonian: Kui patsient seda annust talub, võib annust 1,5 mg kaupa suurendada mitte sagedamini kui kahenädalase intervalliga tavapärase annuseni 3-6 mg kaks korda ööpäevas.
English: In the three studies of Rivastigmine Hexal in patients with Alzheimer's dementia, patients taking doses of Rivastigmine Hexal between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance.
Estonian: Kolmes uuringus Rivastigmine Hexali kasutamise kohta Alzheimeri dementsusega patsientidel paranes Rivastigmine Hexalit annuses 6-9 mg ööpäevas kasutanud patsientidel kognitiivsete sümptomite punktisumma keskmiselt 0,2 punkti võrra, võrreldes 22,9 punktiga uuringu algul (väiksem punktiarv näitab paremat tulemust).
English: The CHMP concluded that Rivastigmine Hexal has a modest effectiveness in treating the symptoms of Alzheimer's dementia, although this does reflect an important benefit in some patients.
Estonian: Inimravimite komitee järeldas, et Rivastigmine Hexali efektiivsus Alzheimeri dementsuse sümptomite ravis on olnud tagasihoidlik, kuigi mõnel patsiendil on sellest olnud oluliselt kasu.
English: Rivastigmine Hexal is also used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Estonian: Rivastigmine Hexalit kasutatakse ka kerge kuni mõõdukalt raskekujulise dementsuse raviks Parkinsoni tõvega patsientidel.
English: Rivastigmine Hexal must not be used in people who are hypersensitive (allergic) to rivastigmine, other carbamate derivatives or any of the other ingredients.
Estonian: Rivastigmine Hexalit ei tohi kasutada patsiendid, kes on rivastigmiini, karbamaadi derivaatide või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Rivastigmine Hexal was also studied in 541 patients with dementia due to Parkinson's disease.
Estonian: Rivastigmine Hexali kasutamist uuriti ka 541 patsiendil, kellel oli Parkinsoni tõvega kaasnev dementsus.
English: Rivastigmine Hexal is a medicine containing the active substance rivastigmine.
Estonian: Rivastigmine Hexal on ravim, mis sisaldab toimeainena rivastigmiini.
English: It must also not be used in patients who are suspected to have had in the past an allergic reaction called ‘allergic contact dermatitis' to Exelon patch.
Estonian: Rivastigmine Hexalit ei tohi kasutada ka patsientidel, kellel võis varem olla Exeloni plaastri suhtes allergiline reaktsioon: allergiline kontaktdermatiit.
English: Rivastigmine Hexal was more effective than placebo at controlling symptoms.
Estonian: Rivastigmine Hexal oli sümptomite leevendamisel platseebost efektiivsem.
English: The types of side effects seen with Rivastigmine Hexal depend on the type of dementia it is being used to treat.
Estonian: Rivastigmine Hexali kõrvalnähud sõltuvad dementsuse liigist, mille raviks seda kasutati.
English: For the full list of all side effects reported with Rivastigmine Hexal, see the package leaflet.
Estonian: Rivastigmine Hexali kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: For the global score, patients taking Rivastigmine Hexal had an increase in symptoms of 4.1 points, compared with 4.4 in those taking placebo.
Estonian: Üldiste sümptomite punktisummat silmas pidades paranes Rivastigmine Hexalit kasutanud patsientidel sümptomite punktisumma 4,1 punkti võrra, võrreldes 4,4 punktiga platseebot kasutanud patsientidel.
English: This is a summary of the European public assessment report (EPAR) for Rivastigmine Hexal.
Estonian: See on ravimi Rivastigmine Hexal Euroopa avaliku hindamisaruande kokkuvõte.
English: The patients with dementia due to Parkinson's disease taking Rivastigmine Hexal capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points.
Estonian: Parkinsoni tõvega kaasneva dementsusega patsientidel, kes kasutasid Rivastigmine Hexalit, paranesid kognitiivsed sümptomid 2,1 punkti võrra, võrreldes halvenemisega 0,7 punkti võrra platseebot kasutanud patsientidel (uuringu alguses oli punktisumma ligikaudu 24).
English: What is the risk associated with Rivastigmine Hexal?
Estonian: Mis riskid Rivastigmine Hexaliga kaasnevad?
English: The global symptom score also improved more in the patients taking Rivastigmine Hexal.
Estonian: Rivastigmine Hexalit kasutanud patsientidel paranes ka üldiste sümptomite punktisumma rohkem.
English: Treatment with Rivastigmine Hexal should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease.
Estonian: Ravi Rivastigmine Hexaliga tohib alustada üksnes Alzheimeri tõve või Parkinsoni tõvega kaasneva dementsuse diagnoosimises ja ravis kogenud arst ning see peab toimuma tema järelevalve all.
English: Why has Rivastigmine Hexal been approved?
Estonian: Miks Rivastigmine Hexal heaks kiideti?
English: The active substance in Rivastigmine Hexal, rivastigmine, is an antidementia medicine.
Estonian: Rivastigmine Hexali toimeainena sisalduv rivastigmiin on dementsuseravim.
English: How is Rivastigmine Hexal used?
Estonian: Kuidas Rivastigmine Hexalit kasutatakse?
English: How has Rivastigmine Hexal been studied?
Estonian: Kuidas Rivastigmine Hexalit uuriti?
English: What is Rivastigmine Hexal used for?
Estonian: Milleks Rivastigmine Hexalit kasutatakse?
English: What is Rivastigmine Hexal?
Estonian: Mis on Rivastigmine Hexal?
English: What benefit has Rivastigmine Hexal shown during the studies?
Estonian: Milles seisneb uuringute põhjal Rivastigmine Hexali kasulikkus?
English: How does Rivastigmine Hexal work?
Estonian: Kuidas Rivastigmine Hexal toimib?
English: Other information about Ciambra
Estonian: Muu teave Ciambra kohta
English: It is given once every three weeks as an infusion lasting 10 minutes.
Estonian: Ciambrat manustatakse iga kolme nädala järel 10-minutilise infusioonina.
English: What measures are being taken to ensure the safe and effective use of Ciambra?
Estonian: Mis meetmed võetakse, et tagada Ciambra ohutu ja efektiivne kasutamine?
English: The full EPAR and risk management plan summary for Ciambra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Ciambra kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Ciambra is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Ciambra võimalikult ohutu kasutamine.
English: The Committee recommended that Ciambra be approved for use in the EU.
Estonian: Komitee soovitas Ciambra kasutamise Euroopa Liidus heaks kiita.
English: What is Ciambra and what is it used for?
Estonian: Mis on Ciambra ja milleks seda kasutatakse?
English: Ciambra is a ‘generic medicine'.
Estonian: Ciambra on geneeriline ravim.
English: This results in the division of cancer cells being reduced, while normal cells are only slightly affected.
Estonian: Selle tulemusena väheneb vähirakkude jagunemine ja normaalseid rakke kahjustatakse vähe.
English: Why is Ciambra approved?
Estonian: Miks Ciambra heaks kiideti?
English: Ciambra is a cancer medicine used to treat two types of lung cancer:
Estonian: Ciambra on vähiravim, mida kasutatakse kaht tüüpi kopsuvähi raviks:
English: Because Ciambra is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Ciambra on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This is a summary of the European public assessment report (EPAR) for Ciambra.
Estonian: See on ravimi Ciambra Euroopa avaliku hindamisaruande kokkuvõte.
English: As a result, the active form of pemetrexed slows down the formation of DNA and RNA and prevents the cells from dividing and multiplying.
Estonian: Selle tulemusena aeglustab pemetrekseedi aktiivne vorm DNA ja RNA moodustumist ning takistab rakkude jagunemist.
English: No additional studies were needed as Ciambra is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Estonian: Lisauuringuid ei olnud vaja, sest Ciambra on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Alimta.
English: • malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery;
Estonian: • pleura maliigne mesotelioom (kopsukelme vähk, mida tavaliselt põhjustab kokkupuude asbestiga), kusjuures Ciambrat kasutatakse koos tsisplatiiniga patsientidel, kes ei ole varem keemiaravi saanud ja kelle vähkkasvajat ei saa kirurgiliselt eemaldada;
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ciambra, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Ciambra omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It can also be used as a maintenance treatment in patients who have received a platinum-based chemotherapy.
Estonian: Ciambrat tohib kasutada ka säilitusraviks patsientidel, kes on saanud plaatinaravimitega keemiaravi.
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Ciambra.
Estonian: Kõrvalnähtude vähendamiseks peab patsient võtma kortikosteroidi (teatud põletikuvastane ravim) ja foolhapet (teatud vitamiin) ning talle tuleb Ciambra-ravi ajal süstida B12-vitamiini.
English: Ciambra contains the active substance pemetrexed.
Estonian: Ciambra sisaldab toimeainena pemetrekseedi.
English: It is not intended to provide practical advice on how to use Ciambra.
Estonian: Hindamisaruandes ei anta Ciambra kasutamise praktilisi nõuandeid.
English: Ciambra pemetrexed
Estonian: Ciambra pemetrekseed
English: This means that Ciambra is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
Estonian: See tähendab, et Ciambra on sarnane võrdlusravimiga Alimta, millel juba on Euroopa Liidus müügiluba.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ciambra has been shown to be comparable to Alimta.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Ciambra sarnane toime ravimiga Alimta.
English: How does Ciambra work?
Estonian: Kuidas Ciambra toimib?
English: The medicine can only be obtained with a prescription and should only be given under the supervision of a doctor who is qualified in the use of chemotherapy.
Estonian: Ciambra on retseptiravim ja seda tohib manustada üksnes keemiaravi kasutamises kogenud arsti järelevalve all.
English: For practical information about using Ciambra, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Ciambra kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.